Efficacy Analysis Of Camrelizumab Combined With TP In The Treatment Of Advanced Esophageal Squamous Cell Carcinoma

Objective: By observing the efficacy and adverse effects of camrelizumab combined with TP(nab-paclitaxel and cisplatin)chemotherapy in the treatment of patients with advanced esophageal squamous cell carcinoma,and evaluation and analysis,to provide more opportunities for clinical treatment of advanced esophageal squamous cell carcinoma.Method: A total of 67 patients with advanced esophageal squamous cell carcinoma admitted to Inner Mongolia Forestry General Hospital from January 2021 to June 2022 were selected and divided into experimental group(n=35 cases)and control group(n=32 cases),according to the patients’ wishes.The experimental group: camrelizumab 200 mg,nab-paclitaxel260mg/m2,cisplatin 75mg/m2,d1,intravenous drip,every 21 days for a cycle;The control group: nab-paclitaxel 260mg/m2,cisplatin 75mg/m2,d1,intravenous infusion,every 21 days for a cycle.The efficacy was assessed after two treatment cycles per treatment.Adverse events were observed during each treatment cycle.The primary observation endpoint,secondary observation endpoint and frequency of adverse events were summarized and analyzed.Result: 1.Short-term efficacy: The objective response rate of the experimental group and control group were 40.0% and 15.63% respectively(P=0.027),and the disease control rate were85.71% and 59.38% respectively(P=0.015).The objective response rate and disease control rate of the experimental group were higher than the control group,the differences were statistically significant(P<0.05).2.Survival analysis:Median progression-free survival of the experimental group and the control group was 7.6 months and 5.7 months,respectively(P=0.039),and the survival of the experimental group was longer than that of the control group,with a statistically significant difference(P<0.05).3.Adverse reactions: The incidence of leukopenia in the experimental group and control group were 42.86% and 53.13%,respectively(P=0.368);the incidence of anemia were 25.71% and 21.88%,respectively(P=0.323);the incidence of thrombocytopenia were 17.14% and 21.88%,respectively(P=0.625);the incidence of neutropenia were 48.57% and 43.75%,respectively(P=0.840);the incidence of nausea were48.57% and 53.13%,respectively(P=0.710);the incidence of vomiting were 37.14% and34.38%,respectively(P=0.517);the incidence of fatigue were 51.43% and 46.86%,respectively(P=0.710);the incidence of abnormal liver function were 45.71% and 50.0%,respectively(P=0.726);the incidence of hypothyroidism were 8.57% and 3.13%,respectively(P=0.335);the incidence of rash were 14.29% and 9.38%,respectively(P=0.809).Conclusion: Camrelizumab combined with TP chemotherapy showed statistically significant differences in objective response rate,disease control rate and progression-free survival in patients with advanced esophageal squamous cell carcinoma compared with TP chemotherapy alone.In the incidence of adverse events,there was no statistically significant difference between the experimental group and the control group,which can provide reference for clinical treatment of advanced esophageal squamous cell carcinoma.